Jio Platforms and SES a leading global satellite-based content connectivity solutions provider today announced the formation of a joint venture Jio Space Technology to deliver the next generation scalable and affordable broadband services in India leveraging satellite technology JPL and SES will own 51Percentage and 49Percentage equity stake in the joint venture respectively The joint venture will use multi-orbit space networks that is a combination […]
Svam Software announced that an Extra Ordinary General Meeting EGM of the Company will be held on 7 March 2022
Cummins India announced that an Extra Ordinary General Meeting EGM of the Company will be held on 10 March 2022
Glenmark Pharmaceuticals today announced that its subsidiary Glenmark Pharmaceuticals Colombia SAS and Astrazeneca Colombia SAS have entered into an exclusive licensing agreement for the commercialization of Astrazenecas drug Pulmicort Respules Under the terms of the agreement Astrazeneca remains the holder of the registration for Pulmicort Respules and will be responsible for manufacturing and supplying the drug Glenmark will be responsible for commercialization of Pulmicort Respules […]
Rama Steel Tubes announced that the Board of Directors of the Company at its meeting held on 14 February 2022 has recommended a Interim dividend of Rs050 per share ie10Percentage subject to the approval of the shareholders
Jonjua Overseas will hold a meeting of the Board of Directors of the Company on 21 February 2022
DIC India announced that the 74th Annual General Meeting AGM of the company will be held on 22 March 2022
Ashiana Housing announced that the Board of Directors of the Company at its meeting held on 14 February 2022 has recommended a Interim dividend of Rs040 per share ie20Percentage subject to the approval of the shareholders
Kilburn Office Automation announced that an Extra Ordinary General Meeting EGM of the Company will be held on 8 March 2022
Zydus US subsidiary Zydus Pharmaceuticals USA Inc has received final approval from the USFDA to market Roflumilast Tablets in the strength of 500 mcg and a tentative approval for Roflumilast Tablets 250 mcg US RLD – DALIRESP Zydus being one of the first applicants for Roflumilast Tablets 500 mcg is eligible for 180 days of shared generic drug exclusivity under section 505j5Biv of the FDC […]
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
